European Journal of Heart Failure

(ISSN: 1388-9842,1879-0844)

This journal no longer participates in Medscape Publishers' Circle Program. No new articles will be republished.

Articles Available on Medscape

 
 

Table of Contents

From European Journal of Heart Failure

2020 -

  • OUTSTEP-HF: Randomised controlled trial comparing short-term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction. 
  • Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without SGLT2 inhibitor therapy in DECLARE-TIMI 58. 
  • Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis. 
  • Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study. 
  • Acknowledging the complex puzzle that links heart failure hospitalizations to outcomes. Letter regarding the article 'Readmission and death in patients admitted with new-onset versus worsening of chronic heart failure: insights from a nationwide cohort'. 
  • Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization. 
  • Worsening renal function after diuresis among heart failure patients with preserved ejection fraction: a dilemma to heart failure management. Letter regarding the article 'Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAX-AHF-2 study'. 
  • Response to the letter regarding the article 'Transcatheter tricuspid valve repair in the setting of heart failure with preserved or reduced left ventricular ejection fraction'. 
  • Letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'. 
  • European Society of Cardiology Working Group on Adult Congenital Heart Disease and Study Group for Adult Congenital Heart Care in Central and South Eastern European Countries consensus paper: current status, provision gaps and investment required. 
  • Hospitalizations for heart failure and mortality risk during the evolving coronavirus disease 2019 pandemic - the wave may break but a dangerous undertow persists. 
  • Letter regarding the article 'Transcatheter tricuspid valve repair in the setting of heart failure with preserved or reduced left ventricular ejection fraction'. 
  • Trial characteristics associated with under-enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review. 
  • Measuring physical activity with activity monitors in patients with heart failure: from literature to practice. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. 
  • Spironolactone discontinuation in patients with heart failure: complex interactions with loop diuretics. Letter regarding the article 'Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT'. 
  • Frequency, trends and institutional variation in 30-day all-cause mortality and unplanned readmissions following hospitalisation for heart failure in Australia and New Zealand. 
  • Natural history and impact of treatment with tafamidis on major cardiovascular outcome-free survival time in a cohort of patients with transthyretin amyloidosis. 
  • Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). 
  • Telemonitoring in patients with chronic heart failure and moderate depressed symptoms: results of the Telemedical Interventional Monitoring in Heart Failure (TIM-HF) study. 
  • Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. 
  • Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease. 
  • Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial. 
  • Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction. 
  • Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. 
  • The impact of palliative care on clinical and patient-centred outcomes in patients with advanced heart failure: a systematic review of randomized controlled trials. 
 
 

Journal Information

Mission Statement: The European Journal of Heart Failure is the International Journal of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure.